EDSA
Edesa Biotech, Inc.1.4850
-0.0049-0.33%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
12.38MP/E (TTM)
-Basic EPS (TTM)
-1.27Dividend Yield
0%Recent Filings
8-K
Phase 3 success for paridiprubart
Edesa Biotech announced positive Phase 3 data for paridiprubart on February 24, 2026, showing a statistically significant 27% relative reduction in 28-day mortality across 278 patients, dropping from 33% to 24% versus placebo plus standard care. Benefits held steady across severity levels and comorbidities. In 174 milder non-IMV patients, mortality fell 35% to 15%. Data bolsters the anti-TLR4 antibody's broad potential.
10-Q
Q1 FY2026 results
Edesa Biotech posted a $2.3M operating loss for Q1 FY2026 ended December 31, 2025, up 23% y/y from $1.9M, driven by $1.1M R&D (EB06 vitiligo ramp-up) and $1.2M G&A featuring $0.4M share-based comp. Net loss narrowed to $2.2M or $0.28/share from $1.6M or $0.48/share, thanks to more shares outstanding (7.97M vs 3.35M). Cash burn slowed to $2.1M (operating cash flow), offset by $3.4M ATM equity raise; quarter-end cash hit $12.1M with $12.0M working capital. Grant income dipped to $0.1M from $0.3M under SRF deal. Cash funds operations briefly. Funding remains tight.
10-K
FY2025 clinical wins
Edesa Biotech's FY2025 ended September 30, 2025 delivered clinical milestones over financials, with no revenue or profitability disclosed in the 10-K. Q4 momentum surged as paridiprubart (EB05) met primary and secondary endpoints in a truncated Phase 3 ARDS study, slashing 28-day mortality 13% versus placebo (39% vs 52%) and cutting IMV needs. EB06 gained Health Canada Phase 2 approval for vitiligo, targeting mid-2026 enrollment. No quarterly financial breakdowns provided. Cash position supports pipeline, bolstered by C$37M in grants. Funding remains precarious.
8-K
ATM offering capacity increased
Edesa Biotech filed a prospectus supplement on December 12, 2025, boosting its at-the-market offering capacity under the October 2024 ATM agreement with H.C. Wainwright to $2.3M. It has already sold $3.7M under the prior prospectus and $837K under the October supplement. Shares remain available for flexible funding. Legal opinion confirms validity.
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
CYDY
CytoDyn Inc.
0.32+0.02
EQ
Equillium, Inc.
1.21-0.01
ESLA
Estrella Immunopharma, Inc.
1.63-0.18
EWTX
Edgewise Therapeutics, Inc.
22.77-1.17
IFRX
InflaRx N.V.
1.04+0.04
UPB
Upstream Bio, Inc.
29.32+2.12
VIR
Vir Biotechnology, Inc.
6.48-0.24
XBIT
XBiotech Inc.
2.45-0.08
ZVSA
ZyVersa Therapeutics, Inc.
0.13-0.00